Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Cytotoxic and DNA-binding Capacity of Titanocene Functionalized Mesoporous Nanoparticles in Breast Cancer Cell Lines MCF-7 and MDA-MB-231

Author(s): Álvar Serrano-Pindado, Michael Aondona Iorhemba, Diana Díaz-García, Miguel Díaz-Sánchez, Irene Mena-Palomo, Santiago Gómez-Ruiz* and Sanjiv Prashar*

Volume 29, Issue 22, 2023

Published on: 07 August, 2023

Page: [1791 - 1799] Pages: 9

DOI: 10.2174/1381612829666230727115356

Price: $65

conference banner
Abstract

Aims: The fight against cancer is an active research topic that combines several disciplines to find suitable agents to treat various tumours.

Background: Following cisplatin, organometallic compounds, including titanocene derivatives, have been tested as antitumoral agents. However, key issues still need to be addressed in metallodrug chemotherapy relating to solubility, stability, and dosage. Mesoporous silica nanoparticles, being low toxic biocompatible materials with high loading capacity, are ideal candidates to overcome these problems.

Objective: This study aimed to prepare and structurally characterize titanocene functionalized mesoporous silica nanoparticles and evaluate their cytotoxic activity against cancer cells.

Methods: The preparation of titanocene functionalized mesoporous silica nanoparticles was achieved by synthetic protocols, involving either grafting or tethering. Characterization was carried out using standard techniques, FT-IR, XRD, XRF, TEM, and BET. The titanocene functionalized materials were studied as antitumoral agents in the breast cancer lines MCF-7 and MDA-MB-231.

Results: The functionalized MSN showed promising antitumoral activity against cells lines MCF-7 and MDAMB- 231 up to 9 times more than titanocene alone.

Conclusion: This study reported the potential of titanocene-functionalized mesoporous silica nanoparticles in future chemotherapeutic actions.

« Previous
[1]
Worldwide Cancer Statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide- cancer (accessed on 15 December 2022).
[2]
Bidram E, Esmaeili Y, Ranji-Burachaloo H, et al. A concise review on cancer treatment methods and delivery systems. J Drug Deliv Sci Technol 2019; 54: 101350.
[http://dx.doi.org/10.1016/j.jddst.2019.101350]
[3]
Kuderer NM, Desai A, Lustberg MB, Lyman GH. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Rev Clin Oncol 2022; 19(11): 681-97.
[http://dx.doi.org/10.1038/s41571-022-00685-3] [PMID: 36221000]
[4]
Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer 2023; 23(2): 78-94.
[http://dx.doi.org/10.1038/s41568-022-00535-5] [PMID: 36471053]
[5]
González-Ballesteros MM, Mejía C, Ruiz-Azuara L. Metallodrugs: An approach against invasion and metastasis in cancer treatment. FEBS Open Bio 2022; 12(5): 880-99.
[http://dx.doi.org/10.1002/2211-5463.13381] [PMID: 35170871]
[6]
Lucaciu RL, Hangan AC, Sevastre B, Oprean LS. Metallo-drugs in cancer therapy: Past, present and future. Molecules 2022; 27(19): 6485.
[http://dx.doi.org/10.3390/molecules27196485] [PMID: 36235023]
[7]
Ma L, Li L, Zhu G. Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives. Inorg Chem Front 2022; 9(11): 2424-53.
[http://dx.doi.org/10.1039/D2QI00205A]
[8]
Banerjee S. Metal-based complexes as potential anti-cancer agents. Anticancer Agents Med Chem 2022; 22(15): 2684-707.
[http://dx.doi.org/10.2174/1871520622666220331085144] [PMID: 35362388]
[9]
Wani WA, Prashar S, Shreaz S, Gómez-Ruiz S. Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs. Coord Chem Rev 2016; 312: 67-98.
[http://dx.doi.org/10.1016/j.ccr.2016.01.001]
[10]
Koepf-Maier P, Koepf H. Non-platinum group metal antitumor agents. History, current status, and perspectives. Chem Rev 1987; 87(5): 1137-52.
[http://dx.doi.org/10.1021/cr00081a012]
[11]
Christodoulou CV, Ferry DR, Fyfe DW, et al. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J Clin Oncol 1998; 16(8): 2761-9.
[http://dx.doi.org/10.1200/JCO.1998.16.8.2761] [PMID: 9704729]
[12]
Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H, Phase II. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 1998; 42(5): 415-7.
[http://dx.doi.org/10.1007/s002800050838] [PMID: 9771957]
[13]
Kröger N, Kleeberg UR, Mross K, Edler L, Hossfeld DK, Phase II. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Oncol Res Treat 2000; 23(1): 60-2.
[http://dx.doi.org/10.1159/000027075]
[14]
Cini M, Bradshaw TD, Woodward S. Using titanium complexes to defeat cancer: The view from the shoulders of titans. Chem Soc Rev 2017; 46(4): 1040-51.
[http://dx.doi.org/10.1039/C6CS00860G] [PMID: 28124046]
[15]
Ellahioui Y, Prashar S, Gómez-Ruiz S. Anticancer applications and recent investigations of metallodrugs based on gallium, tin and titanium. Inorganics 2017; 5(1): 4.
[http://dx.doi.org/10.3390/inorganics5010004]
[16]
Fan R, Chen C, Hou H, et al. Tumor acidity and near-infrared light responsive dual drug delivery polydopamine-based nanoparticles for chemo-photothermal therapy. Adv Funct Mater 2021; 31(18): 2009733.
[http://dx.doi.org/10.1002/adfm.202009733]
[17]
Taleghani AS, Nakhjiri AT, Khakzad MJ, et al. Mesoporous silica nanoparticles as a versatile nanocarrier for cancer treatment: A review. J Mol Liq 2021; 328: 115417.
[http://dx.doi.org/10.1016/j.molliq.2021.115417]
[18]
Díaz-García D, Prashar S, Gómez-Ruiz S. Biological use of nanostructured silica-based materials functionalized with metallodrugs: The spanish perspective. Int J Mol Sci 2023; 24(3): 2332.
[http://dx.doi.org/10.3390/ijms24032332] [PMID: 36768659]
[19]
Ceballos-Torres J, del Hierro I, Prashar S, et al. Alkenyl-substituted titanocene dichloride complexes: Stability studies, binding and cytotoxicity. J Organomet Chem 2014; 769: 46-57.
[http://dx.doi.org/10.1016/j.jorganchem.2014.06.031]
[20]
Zhao Y, Trewyn BG, Slowing II, Lin VSY. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J Am Chem Soc 2009; 131(24): 8398-400.
[http://dx.doi.org/10.1021/ja901831u] [PMID: 19476380]
[21]
Thommes M, Kaneko K, Neimark AV, et al. Physisorption of gases, with special reference to the evaluation of surface area and pore size distribution (IUPAC Technical Report). Pure Appl Chem 2015; 87(9-10): 1051-69.
[http://dx.doi.org/10.1515/pac-2014-1117]
[22]
Mei L, Chen B, Fan R, et al. Magic of architecting oligo-DNAs: 3D structure-dependent stability and programmable specificity to tumor cells. Adv Funct Mater 2022; 32(18): 2112544.
[http://dx.doi.org/10.1002/adfm.202112544]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy